Stoke Therapeutics, Inc. Share Price & Technical Analysis
STOK · $29.34 (-1.11%)
Healthcare / Biotechnology
$29.34
-1.11%
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
-11% return in May, 16% avg return in past 3 year May month.
-2% return in 2026, 79% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -4% | 21% | -8% | 0% | -11% | – | – | – | – | – | – | – | -2% |
| 25 | 4% | -30% | -14% | 48% | -2% | 19% | 15% | 58% | 19% | 28% | 5% | 3% | 154% |
| 24 | -8% | 60% | 75% | -17% | 32% | -9% | 11% | -3% | -15% | 2% | -2% | -8% | 118% |
| 23 | 6% | -10% | -7% | 7% | 19% | -5% | -38% | -14% | -32% | -3% | 0% | 39% | -36% |
| 22 | -21% | 3% | 7% | -32% | -16% | 7% | 11% | 3% | -14% | 15% | -50% | 21% | -65% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Weak
Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.98B
P/E ratio
—
52W high
$40.22
52W low
$9.09
Volume
6,82,772
Beta
1.20
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Stoke Therapeutics, Inc. share price today?
- Stoke Therapeutics, Inc. (STOK) last traded around $29.34 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does STOK have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for STOK. Download the app for real-time alerts.
- How can I analyze Stoke Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.